About Enhancer
| Enhancer ID: | E_00306 |
| Species: | Homo sapiens |
| Position : | chr8:128912000-128913000   |
| Year: | 2018 |
| Title: | Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | breast carcinoma |
| PMID: | 29731168 |
| MONDO: | MONDO:0006120 |
| Tissue: | Breast |
| Tissue Ontology ID: | UBERON:0000310 |
| Cell Source: | MCF-7 |
| CVCL ID: | CVCL_0031 |
| Cell Type: | breast carcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| High Throughput Method: | Hi-ChIP, ATAC-seq, ChIP-seq, RNA-seq |
| Low Throughput Method: | in vitro knockdown, Western blotting |
About Target Gene
| Target gene : | PVT1_INTRAGENIC_ENHANCER_912E |
About TF
| TF name : | MYC |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MYC | AP-1 transcription factor network | pid | 71 |
| MYC | Binding of TCF/LEF:CTNNB1 to target gene promoters | reactome | 7 |
| MYC | C-MYB transcription factor network | pid | 87 |
| MYC | C-MYC pathway | pid | 25 |
| MYC | CD40/CD40L signaling | pid | 36 |
| MYC | Ceramide signaling pathway | pid | 49 |
| MYC | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | reactome | 57 |
| MYC | Constitutive Signaling by NOTCH1 PEST Domain Mutants | reactome | 57 |
| MYC | Cyclin A:Cdk2-associated events at S phase entry | reactome | 15 |
| MYC | Cyclin E associated events during G1/S transition | reactome | 14 |
| MYC | E2F transcription factor network | pid | 77 |
| MYC | EGFR1 | netpath | 475 |
| MYC | Formation of the beta-catenin:TCF transactivating complex | reactome | 88 |
| MYC | FOXM1 transcription factor network | pid | 43 |
| MYC | IL2-mediated signaling events | pid | 54 |
| MYC | IL2 signaling events mediated by PI3K | pid | 38 |
| MYC | IL2 signaling events mediated by STAT5 | pid | 30 |
| MYC | IL6-mediated signaling events | pid | 48 |
| MYC | Interleukin signaling pathway | panther | 86 |
| MYC | LKB1 signaling events | pid | 43 |
| MYC | MAPK6/MAPK4 signaling | reactome | 90 |
| MYC | Notch signaling pathway | pid | 58 |
| MYC | NOTCH1 Intracellular Domain Regulates Transcription | reactome | 47 |
| MYC | Oxidative stress response | panther | 23 |
| MYC | p53 pathway feedback loops 2 | panther | 42 |
| MYC | p73 transcription factor network | pid | 80 |
| MYC | PDGF signaling pathway | panther | 113 |
| MYC | PDGFR-beta signaling pathway | pid | 125 |
| MYC | Presenilin action in Notch and Wnt signaling | pid | 46 |
| MYC | Prolactin | netpath | 105 |
| MYC | Regulation of nuclear beta catenin signaling and target gene transcription | pid | 80 |
| MYC | Regulation of nuclear SMAD2/3 signaling | pid | 82 |
| MYC | Regulation of Telomerase | pid | 70 |
| MYC | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | reactome | 32 |
| MYC | TGF_beta_Receptor | netpath | 220 |
| MYC | Validated nuclear estrogen receptor alpha network | pid | 65 |
| MYC | Validated targets of C-MYC transcriptional activation | pid | 80 |
| MYC | Validated targets of C-MYC transcriptional repression | pid | 63 |
| MYC | MAPK signaling pathway | kegg | 264 |
| MYC | ErbB signaling pathway | kegg | 83 |
| MYC | Cell cycle | kegg | 124 |
| MYC | Wnt signaling pathway | kegg | 135 |
| MYC | TGF-beta signaling pathway | kegg | 82 |
| MYC | Jak-STAT signaling pathway | kegg | 149 |
| MYC | Pathways in cancer | kegg | 321 |
| MYC | Colorectal cancer | kegg | 63 |
| MYC | Endometrial cancer | kegg | 52 |
| MYC | Thyroid cancer | kegg | 25 |
| MYC | Bladder cancer | kegg | 38 |
| MYC | Chronic myeloid leukemia | kegg | 69 |
| MYC | Acute myeloid leukemia | kegg | 53 |
| MYC | Small cell lung cancer | kegg | 83 |
| MYC | Hs_DNA_Damage_Response_(only_ATM_dependent)_WP710_79974 | wikipathways | 36 |
| MYC | Hs_TP53_Network_WP1742_71700 | wikipathways | 10 |
| MYC | Hs_Imatinib_and_Chronic_Myeloid_Leukemia_WP3640_89384 | wikipathways | 11 |
| MYC | Hs_miRNAs_involved_in_DNA_damage_response_WP1545_84697 | wikipathways | 30 |
| MYC | Hs_Association_Between_Physico-Chemical_Features_and_Toxicity_Associated_Pathways_WP3680_90113 | wikipathways | 31 |
| MYC | Hs_Gastric_Cancer_Network_2_WP2363_87523 | wikipathways | 28 |
| MYC | Hs_Hepatitis_C_and_Hepatocellular_Carcinoma_WP3646_88640 | wikipathways | 36 |
| MYC | Hs_Apoptosis_WP254_88977 | wikipathways | 31 |
| MYC | Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 | wikipathways | 122 |
| MYC | Hs_Neural_Crest_Differentiation_WP2064_79263 | wikipathways | 40 |
| MYC | Hs_IL-5_Signaling_Pathway_WP127_78498 | wikipathways | 35 |
| MYC | Hs_Prolactin_Signaling_Pathway_WP2037_90015 | wikipathways | 52 |
| MYC | Hs_EGF-EGFR_Signaling_Pathway_WP437_79266 | wikipathways | 107 |
| MYC | Hs_IL-7_Signaling_Pathway_WP205_89854 | wikipathways | 16 |
Enhancer Associated Network
Expression of Target Genes for the Enhancer